| Argininosuccinate synthetase | |||||||
|---|---|---|---|---|---|---|---|
| Crystallographic structure of human argininosuccinate synthetase.[1] | |||||||
| Identifiers | |||||||
| EC number | 6.3.4.5 | ||||||
| CAS number | 9023-58-9 | ||||||
| Databases | |||||||
| IntEnz | IntEnz view | ||||||
| BRENDA | BRENDA entry | ||||||
| ExPASy | NiceZyme view | ||||||
| KEGG | KEGG entry | ||||||
| MetaCyc | metabolic pathway | ||||||
| PRIAM | profile | ||||||
| PDB structures | RCSB PDB PDBe PDBsum | ||||||
| Gene Ontology | AmiGO / EGO | ||||||
|
|||||||
| Argininosuccinate synthetase 1 | |
|---|---|
| Identifiers | |
| Symbol | ASS1 |
| Entrez | 445 |
| HUGO | 758 |
| OMIM | 603470 |
| RefSeq | NM_000050 |
| UniProt | P00966 |
| Other data | |
| EC number | 6.3.4.5 |
| Locus | Chr. 9 q34.1 |
| crystal structure of thermus thermophilus hb8 argininosuccinate synthetase in complex with atp and citrulline | |||||||||
| Identifiers | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Symbol | Arginosuc_synth | ||||||||
| Pfam | PF00764 | ||||||||
| Pfam clan | CL0039 | ||||||||
| InterPro | IPR001518 | ||||||||
| PROSITE | PDOC00488 | ||||||||
| SCOP | 1kp2 | ||||||||
| SUPERFAMILY | 1kp2 | ||||||||
|
|||||||||
Argininosuccinate synthase or synthetase (ASS) (EC 6.3.4.5) is an enzyme that catalyzes the synthesis of argininosuccinate from citrulline and aspartate
ASS is responsible for the third step of the urea cycle and one of the reactions of the citrulline-NO cycle.
|
Contents
|
The gene that encodes for this enzyme, ASS, is located on chromosome 9. In humans, ASS is expressed mostly in the cells of liver and kidney.
Citrullinemia: At least 50 mutations that cause type I citrullinemia have been identified in the ASS gene. Most of these mutations substitute one amino acid for another in ASS. These mutations likely affect the structure of the enzyme and its ability to bind to citrulline, aspartate, and other molecules. A few mutations lead to the production of an abnormally short enzyme that cannot effectively play its role in the urea cycle.
Defects in ASS disrupt the third step of the urea cycle, preventing the liver from processing excess nitrogen into urea. As a result, nitrogen (in the form of ammonia) and other byproducts of the urea cycle (such as citrulline) build up in the bloodstream. Ammonia is toxic, particularly to the nervous system. An accumulation of ammonia during the first few days of life leads to poor feeding, vomiting, seizures, and the other signs and symptoms of type I citrullinemia.
Treatment for this defect includes a low-protein diet and dietary supplementation with arginine and phenylacetate. Arginine allows the urea cycle to complete itself, creating the substrates needed to originally fix ammonia. This will lower blood pH. Additionally, phenylacetate reacts with backed-up glutamine, resulting on phenylacetoglutamine, which can be excreted renally.[2]
Defects in this protein have been seen in 87% of pancreatic cancers. Cancer cells are therefore unable to synthesis enough arginine for cellular process and so must rely on dietary arginine. Depletion of plasma arginine using arginine deiminase has been shown to lead to regression of tumours in mice.[3]
|
|||||||||||||
|
||||||||||||||
|
|||||||||||
|
|||||||||||
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)